The abstract is read at the publisher; the summary is JClub's.
Immediate linezolid modification after non-severe peripheral neuropathy onset during MDR/RR-TB treatment yields a weighted treatment success probability of 84.1% (95% CI 70.5–93.0%) in 303 participants.
- Why it matters: Peripheral neuropathy often forces linezolid dose reductions or interruptions, but the effect of timing and strategy on MDR/RR-TB treatment success is uncertain.
- What they did: Using the endTB Observational Study, investigators emulated a per-protocol trial by cloning and censoring data with inverse probability of censoring weights, comparing immediate (Weeks 1–7), deferred (Weeks 8–26), and no change (Weeks 1–26) after neuropathy onset.
- The result: Treatment success ratios versus no change were 0.99 (95% CI 0.84–1.10) for immediate change and 0.92 (95% CI 0.77–1.01) for deferred change, showing no evidence of a substantial negative impact.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.